International and Stakeholder Perspectives

Chris Henshall

Associate Professor, Brunel University Honorary Fellow, University of York

Context

Reflections from the perspectives of

- the UK (not just NICE)
- European discussions
- HTAi meetings and discussions
- HTAi Policy Forum
- Work with WHO, PAHO and others, particularly in middle and low income countries

Issues, challenges and questions (1)

Systematic analysis and explanation of the different available approaches to HTA to inform payment/reimbursement decisions, and their pros and cons in relation to the aims, context and constraints associated with different health care systems and the societies they serve

Issues, challenges and questions (2)

 Estimating the overall value for money of the health care system and judging the threshold for acceptability of a new intervention

Issues, challenges and questions (3)

- Managed Entry
 - Optimising decision making under conditions of material uncertainty
 - Understanding potential impact of different uncertainties
 - Options and choices to minimise risk
 - Value of information
 - Collection and analysis of observational data (including stopping and decision rules)

Issues, challenges and questions (4)

- Regulatory/Reimbursement interface and faster access for promising interventions
 - comparative/relative effectiveness
 - Estimating without head to head trials
 - Surrogate endpoints
 - Ongoing data collection and analysis for "fast-tracked" interventions
 - Collection and analysis of observational "real world" data after initial/provisional decisions
 - International standards for analysis and reporting of comparative effectiveness

Issues, challenges and questions (5)

- Efficiency (of HTA)
 - Standards for analysis and reporting to promote value of analyses to other jurisdictions
 - 80/20 rule can we develop some standards or guidance for affordable, "good enough" HTA?

Issues, challenges and questions (6)

- Communication and uptake
 - Simple compelling explanations of key principles and approaches for non technical experts (patients, clinicians, payers and politicians)